Xilio Therapeutics, Inc.
XLO
$0.71
-$0.03-4.44%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 742.51% | 242.98% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 742.51% | 242.98% | -- | -- | -- |
| Cost of Revenue | 33.11% | 36.68% | -- | -- | -- |
| Gross Profit | 155.85% | 18.21% | -- | -- | -- |
| SG&A Expenses | 5.82% | 22.44% | 38.70% | 1.92% | -0.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.02% | 31.82% | 1.46% | -15.32% | -1.70% |
| Operating Income | 86.97% | 2.10% | 16.25% | 24.83% | 14.73% |
| Income Before Tax | -16.17% | -13.78% | 22.89% | 25.84% | 16.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.17% | -13.78% | 22.89% | 25.84% | 16.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.17% | -13.78% | 22.89% | 25.84% | 16.29% |
| EBIT | 86.97% | 2.10% | 16.25% | 24.83% | 14.73% |
| EBITDA | 88.98% | 1.71% | 17.04% | 25.04% | 14.66% |
| EPS Basic | 48.85% | 3.50% | 71.18% | 68.41% | 63.70% |
| Normalized Basic EPS | 49.03% | 3.29% | 69.51% | 68.41% | 63.58% |
| EPS Diluted | 48.85% | 3.50% | 71.18% | 68.41% | 63.70% |
| Normalized Diluted EPS | 49.03% | 3.29% | 69.51% | 68.41% | 63.58% |
| Average Basic Shares Outstanding | 127.06% | 17.92% | 167.62% | 134.70% | 130.58% |
| Average Diluted Shares Outstanding | 127.06% | 17.92% | 167.62% | 134.70% | 130.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |